BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase (collagenase clostridium histolyticum or CCH) is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren’s contracture and for Peyronie's disease in Canada, Europe and Australia.

Endo is partnered with Paladin Labs, Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and/or Peyronie's disease outside of the U.S.

The XIAFLEX and CCH research and development pipeline includes several additional promising indications. Endo is opted-in to manage the development for cellulite, adhesive capsulitis, human and canine lipomas, lateral hip fat and plantar fibromatosis. Endo initiated Phase 3 clinical trials of CCH for the treatment of cellulite in February 2018 with top-line results expected in the fourth quarter of 2018. BioSpecifics is managing the development of CCH for the treatment of uterine fibroids. A Phase 1 clinical trial is fully enrolled and ongoing with top-line results expected in the fourth quarter of 2018.